Pasteur Institute

BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million

Retrieved on: 
화요일, 5월 7, 2024
Public, University, GSK plc, Investment, Health, Bacteria, Partnership, Research, Ethionamide, Pasteur Institute, Disease, GSK, Patient, CHF, Acinetobacter baumannii, MDR, TB, Series, Tuberculosis, Pharmaceutical industry

The compound represents a totally new concept of overcoming resistance and significantly potentiating the activity of an existing antibiotic, ethionamide (Eto).

Key Points: 
  • The compound represents a totally new concept of overcoming resistance and significantly potentiating the activity of an existing antibiotic, ethionamide (Eto).
  • As part of the expanded collaboration, GSK will take an equity stake in BioVersys' latest investment round.
  • Adding to further investments from existing and new investors, this extends the Series C financing by CHF 12.3 million, resulting in total proceeds of CHF 44.9 million for the Series C round to date.
  • Dr. Marc Gitzinger, Chief Executive Officer and founder of BioVersys: "We are very pleased to announce both the expansion of our highly successful strategic collaboration with GSK and our partner’s participation in our latest financing round.

SpikImm Announces the Signature of an Exclusive License Option and Collaboration Agreement With SATT Conectus for the Development of a Prophylactic Treatment Against the BK Virus, Causing Severe Complications in Transplant Patients

Retrieved on: 
화요일, 4월 16, 2024
COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, Other Health, Health, Other Science, Science, Infection, Antibody, University, Bone marrow, Pasteur Institute, BK, Hospital, Kidney, Risk, SARS-CoV-2, Viral, Heart, MD, Doctor of Philosophy, Vaccine, Life, BK virus, European, Disease, System, Transplant, ANR, Patient, Doctor of Pharmacy, CHU, Hemorrhagic cystitis, LFB, Immunodeficiency, BKV, Bladder cancer, University of Strasbourg

This agreement reinforces SpikImm's portfolio and expertise for the prophylactic treatment of viral infections in immunocompromised patients.

Key Points: 
  • This agreement reinforces SpikImm's portfolio and expertise for the prophylactic treatment of viral infections in immunocompromised patients.
  • BK virus (BKV) infects most individuals early in life and typically remains latent in the body without causing disease.
  • However, under immunosuppressive treatment, in particular in transplant patients, BKV can reactivate and replicate in the urinary tract, leading to potentially serious complications.
  • SpikImm and SATT Conectus today announced the signature of an exclusive option agreement for the anti-BKV monoclonal antibodies.

Sensorion Reports Full-Year 2023 Financial Results and Business Update

Retrieved on: 
목요일, 3월 14, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bioreactor, Malignancy, Cell, Chemistry, Patient, Orphan, Good manufacturing practice, Health care, CMC, G&A, Molecular biology, Quality of life, European Medicines Agency, Science, Clinical trial, Cisplatin, Therapy, Hertz, Neoplasm, CIO, Congress, Huber loss, Partnership, Ageing, EMA, Hearing loss, GMP, Cochlea, Biochemistry, Safety, Language, Perilymph, G7, Medication, Control, AAV, PTA, IHC, Pasteur Institute, CDMO, Communication, Genetics, Research, KOL, Ear, POC, FDA, Ototoxicity, GJB2, ABR, CTA, ANSM, Audiogram, Platinum, Investment company, Congenital hearing loss, Pathology, Presbycusis, Hearing, Pharmaceutical industry

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.

Key Points: 
  • Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “Over the past months, Sensorion has successfully achieved all the major milestones on its roadmap.
  • In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV SENS-501 clinical batches at 200L scale.
  • On April 6, 2023, Sensorion announced the candidate selection for GJB2-GT during its gene therapy focused R&D Day.

Sensorion Announces a €50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors

Retrieved on: 
금요일, 2월 9, 2024
Health, Medical Devices, Genetics, Research, Science, Pharmaceutical, Biotechnology, Stifel, Sofinnova, Ototoxicity, Quality of life, GJB2, Huber loss, Euronext Growth, Code, Chair, SVB Securities, EUR, Pasteur Institute, Clinical trial, Patient, Reserved, Person, Commercial code, Audiology

The settlement-delivery of the Reserved Offering is expected to take place around February 13, 2024, subject to customary conditions.

Key Points: 
  • The settlement-delivery of the Reserved Offering is expected to take place around February 13, 2024, subject to customary conditions.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “We are delighted to announce today’s successful capital raise of EUR 50.5 million.
  • This strengthened shareholder base reinforces Sensorion’s ambition to advance its pipeline of innovative therapies intended to improve the quality of life of patients suffering from hearing disorders.
  • Leerink Partners LLC (“Leerink Partners”) and Stifel Europe AG (“Stifel”) are acting as lead agents in connection with the Reserved Offering.

Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 47th Annual Midwinter Meeting

Retrieved on: 
월요일, 1월 29, 2024
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Doctor of Philosophy, Preclinical development, Poster, Pasteur Institute, ARO

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces its participation in the Association for Research in Otolaryngology (ARO) 47th Annual Midwinter Meeting, taking place on February 03-07, 2024, in Anaheim, California, United States of America.

Key Points: 
  • Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces its participation in the Association for Research in Otolaryngology (ARO) 47th Annual Midwinter Meeting, taking place on February 03-07, 2024, in Anaheim, California, United States of America.
  • Laurent Désiré, PhD, Head of Preclinical Development at Sensorion, will give the following presentations during the ARO meeting:
    The poster will be co-presented with Pr.
  • Jérôme Nevoux, M.D., Ph.D., Hearing Institute, research center of the Institut Pasteur

Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501 (OTOF-GT) into a Phase 1/2 Clinical Trial in some European Countries

Retrieved on: 
금요일, 1월 19, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Huber loss, Research, AAV, Hearing loss, EMA, Doctor of Philosophy, Deafness, Emeritus, Kavli Prize, Disorder, Physiology, Audiology, Safety, Hearing, Congenital hearing loss, Philosophy, CTA, Head, AP-HP, ABR, Pasteur Institute, Parent, Primate, Ageing, Cochlea, Patient, IHC, MD, European Medicines Agency, Partnership, Orphan, Language, Food, AP, FDA, Clinical trial, RHU, Pharmaceutical industry

Audiogene will also assess the clinical safety, performance, and usability of the administration device system under development in partnership with EVEON.

Key Points: 
  • Audiogene will also assess the clinical safety, performance, and usability of the administration device system under development in partnership with EVEON.
  • The design of the study will consist of two cohorts of 2 doses followed by an expansion cohort at the selected dose.
  • The CTA approval follows extensive preclinical studies assessing the safety and efficacy of SENS-501 and successful manufacturing of the gene therapy Drug Product for the clinical trial.
  • Sensorion presented preclinical data that indicated the potential for safe and efficient clinical translation of gene therapy for otoferlin delivered by a dual AAV vector.

Sensorion Announces Partnership With the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders Has Been Extended for Five Years

Retrieved on: 
금요일, 1월 5, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Kavli Prize, Partnership, Pasteur Institute, Research, Congenital hearing loss, Hearing loss, Trial of the century, Deafness, GJB2, Huber loss, Physiology, Emeritus, Patient, Diagnosis, Safety, Pharmaceutical industry

The agreement has been amended to be extended up to December 31, 2028, to promote additional development gene therapy programs.

Key Points: 
  • The agreement has been amended to be extended up to December 31, 2028, to promote additional development gene therapy programs.
  • SENS-501, the most advanced program within the partnership that targets deafness caused by mutations in the gene coding for otoferlin, defined as a priority in 2019, has met its objectives.
  • The successful completion of the efficacy preclinical package in the frame of the collaboration between Sensorion and the Institut Pasteur advanced the program with the development of the OTOF-GT product (SENS-501) towards clinical stage.
  • Three indications, all linked to GJB2 mutations, are currently being evaluated: early presbycusis, progressive hearing loss during childhood, and congenital hearing loss.

Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer

Retrieved on: 
목요일, 1월 4, 2024
Doctor of Pharmacy, Conference, Pasteur Institute, Boehringer Ingelheim, Abivax, CDO, Clinical trial, JPMorgan Chase, Pharma, Altana, Pharmaceutical industry

Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer

Key Points: 
  • Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer
    Paul Gineste brings 25 years of experience in clinical development and strategy with leading international pharmaceutical and biotech companies.
  • Recently, Paul served as Vice President, Clinical Operations at Abivax, where he led the development of drug candidates from discovery through global Phase 3 programs.
  • Paris, France, January 4, 2024 - Evexta Bio SA, a clinical-stage biotechnology company focused on developing first-in-class therapies in oncology, announces the appointment of Paul Gineste as Chief Development Officer (CDO), effective January 1, 2024.
  • Scott Filosi, CEO of Evexta Bio, said: "I am delighted to welcome Paul as the new Chief Development Officer of Evexta Bio.

BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

Retrieved on: 
월요일, 12월 18, 2023
RNA, Entrepreneurship, Epidemic, Partnership, Pasteur Institute, Government, State, African, Messenger, Research, WHO, Excellency, Vaccine, Mortality, Quality control, BNTX, CEPI, Republic, Coalition, Laboratory, BioNTech, COVID-19, HIV, Tuberculosis, World Health Organization, Mpox, Infection, Child

President Paul Kagame of Rwanda, Heads of State and Government from Africa and around the world, leadership of the African Union and European Union, as well as from WHO, Africa CDC and CEPI attended the official inauguration of the BioNTech site in Kigali

Key Points: 
  • President Paul Kagame of Rwanda, Heads of State and Government from Africa and around the world, leadership of the African Union and European Union, as well as from WHO, Africa CDC and CEPI attended the official inauguration of the BioNTech site in Kigali
    KIGALI, Rwanda, December 18, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) has reached the next milestone in the establishment of mRNA vaccine manufacturing capacities in Africa with the inauguration of the Company’s site in Kigali, Rwanda.
  • The Company’s manufacturing site in Kigali could become the first commercial-scale mRNA manufacturing facility on the continent.
  • In 2024, BioNTech expects to complete all buildings on site, including a warehouse, offices and laboratories for quality control.
  • BioNTech plans to conduct clinical trials in Africa for vaccine candidates against malaria, tuberculosis and HIV in 2024.

Pasteur Network and GeoSeeq Foundation Partner to Tackle Climate-Associated Increases in Infectious Disease

Retrieved on: 
화요일, 10월 31, 2023
Laboratory, Global North and Global South, Infection, Health, Therapy, Pasteur Institute, Physician, Climate, Malaria, Pasteur Institute of Dakar, Genomics, COVID-19, Partnership, Dengue virus, Developing country, Public, Cholera, Canine vector-borne disease, Vaccine, Pharmaceutical industry

PARIS and NEW YORK, Oct. 31, 2023 /PRNewswire-PRWeb/ -- The threat of infectious diseases is constant and far-reaching, killing 14 million people annually. Changes in climate are exacerbating infectious disease threats, especially for water- and vector-borne diseases. These increased infectious disease threats are most often distributed in low- and middle-income countries, which experience annual surges in dengue virus, malaria, cholera and other infections. While prevention is the ideal approach to controlling infectious diseases, there is limited cross-border surveillance and coordination to drive prevention and response. Furthermore, despite recent lessons from the COVID-19 pandemic, there is still no global system for infectious disease monitoring. Instead, existing platforms are siloed and single-modality or single-region focused.

Key Points: 
  • Changes in climate are exacerbating infectious disease threats, especially for water- and vector-borne diseases.
  • "This partnership marks an important step toward unlocking untapped potential across a leading global infectious disease network," said Dr. Rebecca Grais, executive director of Pasteur Network.
  • "This partnership marks an important step toward unlocking untapped potential across a leading global infectious disease network," said Dr. Rebecca Grais, executive director of Pasteur Network.
  • "Too often, groups feel isolated in their fight against infectious diseases," said Dr. Amadou Sall, director general of Institut Pasteur de Dakar and president of Pasteur Network.